Breaking News Instant updates and real-time market news.

C

Citi

$68.38

-1.57 (-2.24%)

, WFC

Wells Fargo

$51.42

-1.02 (-1.95%)

09:00
10/12/18
10/12
09:00
10/12/18
09:00

Fly Intel: Pre-market Movers

UP AFTER EARNINGS: Citi (C), up 3%... Wells Fargo (WFC), up 2%... JPMorgan (JPM), up 1.7%. ALSO HIGHER: Microsoft (MSFT), up 3% after Macquarie analyst Sarah Hindlian upgraded the stock to Outperform from Neutral and raised her price target to $121 saying she is taking advantage of the pullback in shares... Corium (CORI), up 50% after agreeing to be acquired by Gurnet Point for $12.50 per share... TSMC (TSM), up 2.5% after DigiTimes reports it will receive all of Apple's (AAPL) A-13 chip orders. DOWN AFTER EARNINGS: PNC Financial (PNC), down 1%. ALSO LOWER: Immune Design (IMDZ), down 42% after announcing it will focus on the development of intratumoral IO agent G100 and discontinue CMB305... Trevena (TRVN), down 7% after announcing a negative outcome of an FDA advisory committee meeting on oliceridine.

C

Citi

$68.38

-1.57 (-2.24%)

WFC

Wells Fargo

$51.42

-1.02 (-1.95%)

JPM

JPMorgan

$108.06

-3.59 (-3.22%)

MSFT

Microsoft

$105.91

-0.39 (-0.37%)

CORI

Corium

$8.32

0.02 (0.24%)

TSM

TSMC

$38.94

-0.42 (-1.07%)

AAPL

Apple

$214.49

-1.89 (-0.87%)

PNC

PNC Financial

$131.62

-4.53 (-3.33%)

IMDZ

Immune Design

$2.80

-0.04 (-1.41%)

  • 12

    Oct

  • 12

    Oct

  • 12

    Oct

  • 16

    Oct

  • 19

    Oct

  • 21

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 13

    Nov

  • 14

    Nov

  • 28

    Nov

  • 14

    Jan

  • 26

    Feb

  • 03

    Mar

  • 12

    Apr

  • 12

    Apr

  • 15

    Apr

  • 13

    Jul

  • 13

    Jul

  • 17

    Jul

  • 12

    Oct

  • 16

    Oct

C Citi
$68.38

-1.57 (-2.24%)

09/19/18
OPCO
09/19/18
NO CHANGE
OPCO
Outperform
U.S. banks 'in very good shape,' says Oppenheimer, favorites include BofA, Citi
Oppenheimer analyst Chris Kotowski tells investors in a research note that the U.S. banking group is on solid footing with balance sheets less risky than at any time over the last 33 years the firm covered the group and says his favorite bank stocks are Outperform-rated Bank of America (BAC), Citi (C), CIT (CIT) and Goldman Sachs (GS). However, Kotowski notes that banks are trading at an average relative P/E of just ~66% relative to the S&P 500 and returning to a historical avg valuation of 73%-80% range would imply over a thousand basis points of outperformance by the group. In his view, the U.S. banks are, on the whole, in "very good" shape.
08/28/18
WELS
08/28/18
NO CHANGE
Target $100
WELS
Outperform
Citi to benefit from potential U.S.-Mexico trade deal, says Wells Fargo
Wells Fargo analyst Mike Mayo believes Citi could gain more than other large U.S. banks from a U.S.-Mexico trade deal given its ownership of the second largest bank in Mexico, Citibanamex. In his view, Citi's stock had been hurt on perceptions of the U.S. relationship with Mexico. At a minimum, any new trade deal could reflect the absence of a negative and, on the upside, new potential growth opportunities, he contends. Mayo reiterates an Outperform rating and $100 price target on the shares.
07/27/18
RHCO
07/27/18
NO CHANGE
Target $240
RHCO
Buy
MasterCard price target raised to $240 from $215 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on MasterCard to $240 and kept his Buy rating, saying the company is demonstrating expansion of global market share while posting a 14% Q2 volume growth. The analyst adds that while MasterCard has a higher valuation than PayPal (PYPL) and Visa (V) - a 10% relative EBITDA premium - it is justified and may even be too narrow given its superior growth sustainability and margin upside.
09/25/18
WOLF
09/25/18
INITIATION
Target $91
WOLF
Outperform
Citi initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Citi with an Outperform and $91 price target.
WFC Wells Fargo
$51.42

-1.02 (-1.95%)

09/12/18
JPMS
09/12/18
NO CHANGE
JPMS
Underweight
Reported OCC rejection would be negative for Wells, says JPMorgan
According to Reuters, Office of the Comptroller of the Currency regulators have rejected Wells Fargo's plan to repay its auto customers who were pushed to buy unnecessary auto insurance, JPMorgan analyst Vivek Juneja tells investors in a research note. This rejection would be a negative for Wells as it may be required to spend more and take more time to satisfy regulators, the analyst writes. He also views the news negatively overall for the bank's ongoing regulatory issues. Juneja reiterates an Underweight rating on shares of Wells Fargo.
09/17/18
EDJN
09/17/18
UPGRADE
EDJN
Buy
Wells Fargo upgraded to Buy from Hold at Edward Jones (Friday)
09/25/18
WOLF
09/25/18
INITIATION
Target $71
WOLF
Outperform
Wells Fargo initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated Wells Fargo with an Outperform and $71 price target.
09/28/18
UBSW
09/28/18
NO CHANGE
Target $63
UBSW
Buy
Wells Fargo app download data suggests no momentum slowdown, says UBS
UBS analyst Saul Martinez reassessed Wells Fargo client engagement and employee sentiment and found that app download data was encouraging and showed no slowdown in momentum. Employee sentiment, however, showed a material weakening. The analyst said meaningful improvements in earnings power and profitability require revenue to stabilize and the recent share weakness may be due to concerns that business momentum and top line growth will continue to lag. Martinez maintained his Buy rating and $63 price target on Wells Fargo shares.
JPM JPMorgan
$108.06

-3.59 (-3.22%)

10/03/18
BERN
10/03/18
NO CHANGE
BERN
Amazon to be accelerant of disruption coming for healthcare, says Bernstein
Bernstein analyst Lance Wilkes believes disruption is coming for healthcare and that Amazon (AMZN) will be an accelerant of this disruption. Further, the analyst sees a parallel with the fast changes in health insurance which took place in the 90's, when health insurance changed from 90% indemnity to 80% managed care within ten years. Wilkes thinks Amazon is developing a series of business strategies for entering healthcare market segments, namely directly entering online pharmacy, creating a disruptor in the employer healthcare space through its venture with Berkshire (BRK.A) and JPMorgan (JPM), and entering digital consumer healthcare spaces including using Alexa for consumer engagement and behavior modification.
09/25/18
WOLF
09/25/18
INITIATION
Target $140
WOLF
Outperform
JPMorgan initiated with an Outperform at Wolfe Research
Wolfe Research analyst Steven Chubak initiated JPMorgan with an Outperform and $140 price target.
08/22/18
DBAB
08/22/18
NO CHANGE
DBAB
JPMorgan mobile launch a catalyst for industry consolidation, says Deutsche
Deutsche Bank analyst Brian Bedell believes JPMorgan's (JPM) reported rollout of online trading to its 47M customers next week should be a catalyst for online broker industry consolidation. The analyst believes the news supports his TD Ameritrade (AMTD), E-Trade (ETFC) merger scenario thesis. He points out that his model already includes "substantial" trade price compression.
08/22/18
SBSH
08/22/18
NO CHANGE
SBSH
JPMorgan mobile trading platform 'another salvo' on online brokers, says Citi
JPMorgan's (JPM) reported zero cost mobile trading service to be launched next week is "another salvo" in the war on broker dealers' fundamentals, Citi analyst William Katz tells investors in a research note. JPMorgan's move further underscores the commoditization risk to pricing across the retail broker dealer complex, particularly online brokers, the analyst adds. Further, he believes the new product adds an additional degree of difficulty to pricing a potential E-Trade (ETFC) acquisition or other retail broker deals. The analyst's work suggests negative 3% and negative 1% earnings risk to TD Ameritrade (AMTD) and Charles Schwab (SCHW), respectively. However, Katz believes much of the negativity is already priced into Ameritrade following yesterday's selloff. For Schwab, he believes continued pressure on Investor Services presents further downside risk in the stock from here.
MSFT Microsoft
$105.91

-0.39 (-0.37%)

10/08/18
FBCO
10/08/18
NO CHANGE
FBCO
Outperform
Global brand ranking validates Microsoft rebranding efforts, says Credit Suisse
Credit Suisse analyst Brad Zelnick notes that, among top global brands, Microsoft (MSFT) ranked fourth in global brand ranking with a brand value of $92.7B, superseded only by Amazon (AMZN), Google (GOOG; GOOGL) and Apple (AAPL). The analyst believes this validates Microsoft's rebranding efforts in the Satya era, distinguished by a more open and flexible approach to customers, rivals as well as application developers. Zelnick reiterates an Outperform rating on Microsoft shares.
10/08/18
BARD
10/08/18
NO CHANGE
BARD
Outperform
Microsoft Project xCloud mostly positive for game publishers, says Baird
After Microsoft (MSFT) announced details of its game-streaming initiative, Project xCloud, Baird analyst Colin Sebastian said he does not expect beta user trials until 2019, with a full launch likely 1-2 years later. The analyst, who sees the news as mostly positive for game publishers Activision Blizzard (ATVI), Electronic Arts (EA) and Take-Two (TTWO), believes that streaming represents an opportunity to convert a portion of the remaining casual gamer market by providing console-quality full streaming games with the cross-platform social features of current consoles. Baird has Outperform ratings on all three game publishers mentioned.
10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Microsoft upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral and raised its price target to $121 saying she is taking advantage of the pullback in shares. Hindlian views Microsoft as a relatively defensive name with long-term earnings power and expects a strong start to FY19 following constructive field work.
10/12/18
MACQ
10/12/18
UPGRADE
Target $121
MACQ
Outperform
Macquarie upgrades Microsoft to Outperform after pullback to 'correct' mistake
As previously reported, Macquarie analyst Sarah Hindlian upgraded Microsoft to Outperform from Neutral, taking advantage of the market pullback to "correct" her rating on "a name [she has sorely missed." The company has been differentiating Azure in several critical ways that she did not fully appreciate, such as being both enterprise-friendly and aggressive in layering in unique and incremental services such as Artificial Intelligence, Azure Stack, Azure Sphere, and a broad focus on edge computing, Hindlian tells investors. Additionally, Microsoft continues to drive the business into higher-growth arenas, like public cloud and what she expects to be an emerging successful gaming services platform. While many are worrying that the company's robust earnings trend will not persist as comps get tougher, Hindlian sees ample revenue drivers and raised her price target on Microsoft shares to $121 from $106.
CORI Corium
$8.32

0.02 (0.24%)

12/27/17
HCWC
12/27/17
NO CHANGE
Target $14
HCWC
Buy
Corium partner's CRL not 'thesis buster,' says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says while the complete response letter received by partner Agile Therapeutics (AGRX) is a negative surprise and a delay to Corium's (CORI) nearest-term revenue driver, it is "not a thesis buster." The issues raised in the CRL are not deal breakers for Twirla, and will likely just delay approval by one year, Livnat tells investors in a research note. He lowered his price target for Corium shares to $14 from $15 but reiterates a Buy rating on the name.
12/26/17
NEED
12/26/17
NO CHANGE
Target $14
NEED
Buy
Corium price target lowered to $14 from $16 at Needham
Needham analyst Serge Belanger lowered his price target on Corium (CORI) to $14 after the FDA's letter on the Twirla contraceptive patch by Agile Therapeutics (AGRX) outlined its deficiencies. Belanger says Twirla was Corium's most near-term revenue opportunity, pushing out its anticipated approval by about 12 months. The analyst keeps his Buy rating on Corium.
12/26/17
JEFF
12/26/17
NO CHANGE
Target $13
JEFF
Buy
Corium's partner's CRL looks addressable, says Jefferies
Jefferies analyst David Steinberg believes the complete repose letter received by Corium's (CORI) partner Agile Therapeutics (AGRX) appears addressable. Management indicated the issues relate to Agile's use of standard square-patch tests to assess its circular patch, Steinberg tells investors in a research note. They believe the adhesion profile is "excellent" and, importantly, data addressing the issue has not yet been reviewed by the FDA, the analyst adds. He notes that Twirla's profitability impact to Corium is relatively low, causing only a modest reduction in out-year estimates from the delayed approval. Steinberg keeps a Buy rating on Corium with a $13 price target.
05/15/18
HCWC
05/15/18
NO CHANGE
Target $14
HCWC
Buy
Corium recent pullback overdone, says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat views the recent pullback in shares of Corium International (CORI) as overdone and unwarranted. The stock is down 30% since the company's recapitalization at the end of February, which "is a bit of a mystery," Livnat tells investors in a research note. The analyst is not aware of any negative fundamental developments for the key pipeline driver, a weekly donepezil patch for Alzheimer's, or any material updates to its partner Agile's (AGRX) Twirla contraceptive patch. He reiterates a Buy rating on Corium with a $14 price target.
TSM TSMC
$38.94

-0.42 (-1.07%)

08/28/18
FBCO
08/28/18
NO CHANGE
Target $13.5
FBCO
Neutral
AMD shares 'more fully valued than cheap,' says Credit Suisse
While the transition to TSMC (TSM) for all 7nm products is a positive for AMD (AMD) given TSMC's "successful record of leading-edge manufacturing," AMD does not expect the transition to impact its long-term financial model, Credit Suisse analyst John Pitzer told investors last night in a research note. Further, the transition could have a dampening near-term financial impact as AMD has pre-negotiated annual purchase targets with GF thru 2020 that requires AMD to make quarterly payments based on the volume of wafers purchased from other foundries, the analyst adds. He notes that the departure of Jim Anderson, who is leaving AMD to become the CEO of Lattice Semiconductor (LSCC), is the latest executive departure at the company. While AMD's intellectual property is "extremely valuable" and investors continue to underestimate accelerating compute demand across all architectures, the stock appears "more fully valued than cheap" at current levels, Pitzer writes. The analyst maintains a Neutral rating on AMD with a $13.50 price target. The chipmaker in early trading is up 41c to $25.67.
09/19/18
09/19/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Transocean (RIG) upgraded to Outperform from Market Perform at Wells Fargo with analyst Judson Bailey saying he "significantly" increased his EBITDA and net asset value estimates across the offshore drilling space to reflect increasing demand combined with tightening availability for high spec ultra-deepwater rigs. 2. TSMC (TSM) upgraded to Overweight from Equal Weight at Morgan Stanley. 3. Mechel (MTL) upgraded to Neutral from Sell at Citi. 4. Juniper (JNPR) upgraded to Buy from Neutral at Nomura Instinet with analyst Jeffrey Kvaal saying he believes Juniper "will finally be able to catch the webscale capex growth tailwind in 2019." 5. E-Trade (ETFC) upgraded to Buy from Hold at Jefferies with analyst Daniel Fannon saying the stock's current valuation is attractive for the core business while the financial and strategic benefits as a takeout candidate remain intact. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/18
MSCO
09/18/18
UPGRADE
MSCO
Overweight
TSMC upgraded to Overweight from Equal Weight at Morgan Stanley
08/29/18
MKMP
08/29/18
NO CHANGE
Target $20
MKMP
Neutral
Advanced Micro Devices price target raised to $20 from $13.50 at MKM Partners
MKM Partners analyst Ruben Roy raised his price target on Advanced Micro Devices (AMD) to $20, citing continued strength of the PC and data center end markets as well as his underestimated "new product momentum". The analyst also sees this week's expected announcement regarding a shift in 7nm production to TSMC (TSM) to benefit its long-term margin structure. Roy keeps his Neutral rating on AMD however, noting that its valuation of 38-times his expected forward earnings already reflects the high expectations.
AAPL Apple
$214.49

-1.89 (-0.87%)

10/09/18
10/09/18
DOWNGRADE

Neutral
Coherent downgraded to Neutral on OLED timing, industrial malaise at Longbow
As previously reported, Longbow analyst Joe Wittine downgraded Coherent (COHR) Neutral from Buy based upon a potentially elongating OLED investment cycle. Wittine views Apple's (AAPL) iPhone XR/LCD dynamic as partially responsible for this extension. Should advanced LCD devices prove to have a longer shelf life, the investment cycle will face extensions, he contends. The analyst also cited the weakening seen in his Q3 industrial laser survey confirmed by IPG Photonics' (IPGP) Q3 preannouncement last week.
10/10/18
BFIN
10/10/18
NO CHANGE
BFIN
BlueFin checks show Lumentum received increased orders from Apple
BlueFin analysts John Donovan and Steve Mullane say their firm's latest supply chain checks suggest "strong and stable" iPhone demand. While unit demand has not changed, the mix to higher storage models has increased, which should benefit Toshiba (TOSBF), Samsung (SSNLF), and Micron Technology (MU), Donovan and Mullane tell investors in a research note. Further, BlueFin's latest checks reveal Lumentum (LITE) has received increased orders recently while competitors II-VI (IIVI) and Finisar (FNSR) continue to focus on securing second-source positioning. The latest on the two latter companies is mixed, but overall "encouraging," the analysts contend. As far as the rumors that Apple is exploring internal VCSEL development, they believe this is "more of a negotiating tactic at this point." VCSEL demand "looks to be skyrocketing" and the frustration in developing a secure second-source has likely caused Apple to explore internal development, write Donovan and Mullane. They understand Apple has looked into fabs in Taiwan to see about VCSEL development but note the earliest this could materialize is 2020-2021. This is likely more of a "call to arms" by Apple for Finisar, II-VI, and Lumentum to increase production to meet the demand, "or else face the consequences."
10/11/18
JPMS
10/11/18
UPGRADE
Target $80
JPMS
Overweight
JPMorgan upgrades Lumentum to Overweight after 19% selloff
JPMorgan analyst Samik Chatterjee upgraded Lumentum to Overweight from Neutral with an unchanged price target of $80. The shares closed yesterday down 3%, or $1.68, to $55.58. The 19% stock decline from the highs in late August, driven by concerns relative to U.S.-China trade, over-appreciates the "modest risks" for Lumentum, Chatterjee tells investors in a research note. He believes this creates an "attractive buying opportunity" to capitalize on the near-term improvement in the earnings outlook The analyst sees an improved outlook for Lumentum's telecom business on 5G investment tailwinds as well as benefits to pricing and market share in the datacom business. Further he expects "strong growth" in 3D sensing revenues on wider adoption of facial recognition technology on Apple (AAPL) iPhones and androids.
10/12/18
WEDB
10/12/18
UPGRADE
Target $6.5
WEDB
Outperform
Fitbit upgraded to Outperform from Neutral at Wedbush
Wedbush analyst Michael Pachter upgraded Fitbit (FIT) to Outperform from Neutral, citing the company's expansion into the healthcare/MedTech vertical. In a research note to investors, Pachter says Fitbit has captured a large share of both the smartwatch and fitness tracker markets, but its watches must compete with Apple's (AAPL) offering. He thinks Fitbit has an "excellent" opportunity ahead with MedTech, particularly in collaboration with Google (GOOG, GOOGL), and believes Fitbit may begin reporting meaningful contribution from MedTech as early as 2019. Pachter also notes that shares have recently pulled back well below his $6.50 price target, providing an opportunity to get involved in the Medtech vertical at a reasonable price.
PNC PNC Financial
$131.62

-4.53 (-3.33%)

07/20/18
OPCO
07/20/18
NO CHANGE
OPCO
Perform
Wells Fargo's next few earnings reports likely to be 'choppy,' says Oppenheimer
Oppenheimer analyst Chris Kotowski maintained a Perform rating on Wells Fargo (WFC) after recent meetings with CFO John Shrewsberry. In a research note to investors, Kotowski says there was nothing that shakes his view that the next few quarterly earnings reports are likely to still be "choppy," and notes that Shewsberry "readily acknowledged" that there was much work to be done to get the consent order lifted. At the same time, the analyst contends that shares are not trading at much of a discount versus other high performing banks like JPMorgan (JPM) and PNC (PNC) and says he favors companies that have lower but rising ROTCEs that are trading near TBV, especially Citi (C), CIT (CIT) and Goldman (GS).
06/14/18
RBCM
06/14/18
NO CHANGE
Target $170
RBCM
Top Pick
PNC Financial EPS view cut at RBC Capital on reduced mortgage banking outlook
RBC Capital analyst Gerard Cassidy lowered his PNC Financial FY18 EPS view to $10.51 from $10.60 and FY19 view to $11.32 from $11.46 after the recent commentary by the management that its Q2 mortgage banking revenues are tracking to be 12% lower than in Q1. The analyst keeps his Top Pick rating and $170 price target however, saying the bank is well positioned for higher interest rates that would expand its net interest income and also has a high 42% of the total component for its non-interest income. Cassidy adds that the regulatory environment benefits could also exceed his expectations.
05/30/18
BARD
05/30/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial added as Fresh Pick at Baird
Baird analyst David George said the weakness in PNC Financial is a buying opportunity and said it screens as one of the better values among regional banks. The analyst likes the bank's competitive positioning, solid intermediate-term outlook, and its current valuation. George reiterated his Outperform rating and $153 price target on PNC Financial shares.
04/16/18
BARD
04/16/18
NO CHANGE
Target $153
BARD
Outperform
PNC Financial weakness overdone, says Baird
Baird analyst David George said PNC Financial posted a clean quarter and he would be a buyer of the shares on the post-earnings weakness. The analyst noted fees were down seasonally, but the bank posted good year-over-year growth. George maintained his Outperform rating and $153 price target on PNC Financial shares.
IMDZ Immune Design
$2.80

-0.04 (-1.41%)

10/12/18
HCWC
10/12/18
NO CHANGE
Target $7.75
HCWC
Buy
Immune Design price target lowered to $7.75 from $11 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered his price target for Immune Design to $7.75 after the company provided two updates to its corporate strategy. The company said its primary focus is being placed on G100 and the initial opportunity in indolent lymphoma patients and that CMB305 is being placed on the back burner following a review of the ongoing Phase 2 combination study with Tecentriq, and the strategic decision to not pursue the Synovate pivotal study in sarcoma patients, which is now discontinued, Pantginis tells investors in a research note. He believes the shares trading below cash "presents an opportunity to participate in the G100 program at ground floor levels." The analyst keeps a Buy rating on Immune Design.
10/12/18
RBCM
10/12/18
NO CHANGE
Target $11
RBCM
Outperform
Immune Design price target lowered to $11 from $15 at RBC Capital
RBC Capital analyst Brian Abrahams lowered his price target on Immune Design to $11 to reflect the impact of the company's announcement to focus on the development of intratumoral IO agent G100 and discontinue CMB305. The analyst adds that while the discontinuation is disappointing "given the promise of that tumor vaccine platform's mechanism", he also sees it a way to "refocus" the investment story and extend the company's cash runway. The analyst keeps his Outperform rating on Immune Design and maintains that shares are undervalued.
10/12/18
LEER
10/12/18
DOWNGRADE
LEER
Market Perform
Immune Design downgraded to Market Perform from Outperform at Leerink
08/29/18
08/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Outperform at Oppenheimer. 2. Systemax (SYX) initiated with a Market Perform at William Blair. 3. Broadridge (BR) initiated with a Buy at SunTrust. 4. Mercury General (MCY) initiated with an Outperform at Keefe Bruyette. 5. Immune Design (IMDZ) initiated with a Buy at H.C. Wainwright. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

02:55
02/20/19
02/20
02:55
02/20/19
02:55
General news
FX Update: The Dollar has traded mostly firmer »

FX Update: The Dollar…

01:55
02/20/19
02/20
01:55
02/20/19
01:55
General news
Asian Market Wrap: »

Asian Market Wrap:…

LUV

Southwest

$57.66

0.02 (0.03%)

21:49
02/19/19
02/19
21:49
02/19/19
21:49
Downgrade
Southwest rating change at Goldman Sachs »

Southwest downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

RARE

Ultragenyx

$56.80

0.14 (0.25%)

21:17
02/19/19
02/19
21:17
02/19/19
21:17
Recommendations
Ultragenyx analyst commentary at Piper Jaffray »

Piper Jaffray positive on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

21:05
02/19/19
02/19
21:05
02/19/19
21:05
General news
Japan's exports fell 8.4% in January »

Japan's exports fell…

PANW

Palo Alto Networks

$230.19

3.46 (1.53%)

20:49
02/19/19
02/19
20:49
02/19/19
20:49
Downgrade
Palo Alto Networks rating change at Gabelli »

Palo Alto Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 25

    Feb

  • 26

    Feb

  • 04

    Mar

  • 05

    Mar

AROC

Archrock

$10.06

0.365 (3.76%)

20:33
02/19/19
02/19
20:33
02/19/19
20:33
Earnings
Archrock sees FY19 net income $73M-$103M vs. $29.2M in FY18 »

Sees FY19 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CTL

CenturyLink

$14.10

0.37 (2.69%)

20:32
02/19/19
02/19
20:32
02/19/19
20:32
Downgrade
CenturyLink rating change at RBC Capital »

CenturyLink downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 11

    Mar

TTD

Trade Desk

$161.76

3.69 (2.33%)

20:31
02/19/19
02/19
20:31
02/19/19
20:31
Downgrade
Trade Desk rating change at Stifel »

Trade Desk downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 06

    Mar

CVS

CVS Health

$69.92

0.39 (0.56%)

, SO

Southern Company

$48.91

0.35 (0.72%)

20:25
02/19/19
02/19
20:25
02/19/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

CVS

CVS Health

$69.92

0.39 (0.56%)

SO

Southern Company

$48.91

0.35 (0.72%)

ADI

Analog Devices

$104.21

-1.49 (-1.41%)

HSIC

Henry Schein

$63.11

0.73 (1.17%)

OC

Owens Corning

$55.38

0.73 (1.34%)

WIX

Wix.com

$125.70

4.31 (3.55%)

WWW

Wolverine World Wide

$39.50

-0.04 (-0.10%)

CNDT

Conduent

$14.52

0.93 (6.84%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 27

    Feb

  • 12

    Mar

  • 18

    Mar

  • 19

    Mar

  • 09

    Apr

  • 28

    May

AROC

Archrock

$10.06

0.365 (3.76%)

20:21
02/19/19
02/19
20:21
02/19/19
20:21
Earnings
Archrock reports Q4 EPS 10c, consensus 8c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AI

Arlington Asset Investment

$8.70

-0.14 (-1.58%)

20:09
02/19/19
02/19
20:09
02/19/19
20:09
Syndicate
Arlington Asset Investment 6M share Spot Secondary priced at $8.33 »

Arlington Asset announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

GLD

SPDR Gold Shares

$126.70

1.89 (1.51%)

19:46
02/19/19
02/19
19:46
02/19/19
19:46
Hot Stocks
SPDR Gold Shares holdings fall to 792.45MT from 793.03MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$305.56

-2.2 (-0.71%)

19:17
02/19/19
02/19
19:17
02/19/19
19:17
Hot Stocks
Tesla CEO says company will make about 500,000 cars in 2019 »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 21

    Feb

  • 25

    Feb

  • 18

    Mar

  • 19

    Mar

IDCC

InterDigital

$73.13

-0.26 (-0.35%)

19:06
02/19/19
02/19
19:06
02/19/19
19:06
Hot Stocks
InterDigital says LG Electronics extends license to use Hillcrest's Freespace »

InterDigital, Inc.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 28

    Mar

TWTR

Twitter

$31.64

0.41 (1.31%)

19:03
02/19/19
02/19
19:03
02/19/19
19:03
Hot Stocks
Tesla CEO says 4,000 cars loading in San Francisco for Europe »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

OSPN

OneSpan

$16.78

0.645 (4.00%)

, HSTM

HealthStream

$26.95

0.09 (0.34%)

19:01
02/19/19
02/19
19:01
02/19/19
19:01
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

OSPN

OneSpan

$16.78

0.645 (4.00%)

HSTM

HealthStream

$26.95

0.09 (0.34%)

LNTH

Lantheus

$19.18

0.67 (3.62%)

CDNS

Cadence Design

$52.65

0.09 (0.17%)

CRMT

America's Car-Mart

$81.74

-0.43 (-0.52%)

DVN

Devon Energy

$28.31

-0.11 (-0.39%)

LMAT

LeMaitre

$25.09

-0.01 (-0.04%)

FIVN

Five9

$54.31

0.1 (0.18%)

NVTA

Invitae

$16.49

0.43 (2.68%)

LZB

La-Z-Boy

$32.23

0.845 (2.69%)

DK

Delek US

$34.87

0.025 (0.07%)

VRSK

Verisk Analytics

$124.45

-0.93 (-0.74%)

WIRE

Encore Wire

$56.32

1.32 (2.40%)

HLF

Herbalife Nutrition

$57.46

0.8 (1.41%)

TVTY

Tivity Health

$21.67

0.28 (1.31%)

IIN

IntriCon

$29.43

2 (7.29%)

LC

LendingClub

$3.62

0.05 (1.40%)

CXO

Concho Resources

$120.95

-2.03 (-1.65%)

FANG

Diamondback Energy

$104.75

-0.78 (-0.74%)

TXRH

Texas Roadhouse

$65.58

0.03 (0.05%)

SSTI

ShotSpotter

$48.18

2.2 (4.78%)

OMI

Owens & Minor

$7.94

0.25 (3.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 19

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 20

    Feb

  • 21

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 27

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 04

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 13

    Mar

  • 13

    Mar

  • 14

    Mar

  • 18

    Mar

  • 28

    Mar

  • 22

    May

  • 28

    May

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:58
02/19/19
02/19
18:58
02/19/19
18:58
Hot Stocks
Hudbay Minerals announces increased reserves at Lalor mine »

Hudbay Minerals announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:56
02/19/19
02/19
18:56
02/19/19
18:56
Hot Stocks
Hudbay Minerals reports Q4 copper output 37.2K tonnes, down 14% from last year »

Reports Q4 gold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

CLXT

Calyxt

$13.56

0.15 (1.12%)

18:55
02/19/19
02/19
18:55
02/19/19
18:55
Hot Stocks
Calyxt, Agtegra Cooperative announce strategic collaboration »

Calyxt and Agtegra…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBM

Hudbay Minerals

$6.35

0.365 (6.10%)

18:54
02/19/19
02/19
18:54
02/19/19
18:54
Earnings
Hudbay Minerals reports Q4 EPS (1c), consensus 18c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

NOC

Northrop Grumman

$287.36

0.44 (0.15%)

18:39
02/19/19
02/19
18:39
02/19/19
18:39
Hot Stocks
Northrop Grumman recommends shareholders to reject offer by TRC Capital »

Northrop Grumman has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

18:31
02/19/19
02/19
18:31
02/19/19
18:31
Periodicals
POTUS says U.S. corn sales to China part of trade talks, Bloomberg says »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$277.89

0.49 (0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$9.69

0.11 (1.15%)

18:29
02/19/19
02/19
18:29
02/19/19
18:29
Hot Stocks
Aphria announces early termination of Liberty Health Sciences divestment »

Aphria announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEVA

Teva

$18.01

0.02 (0.11%)

, AGN

Allergan

$137.94

-1.13 (-0.81%)

18:26
02/19/19
02/19
18:26
02/19/19
18:26
Hot Stocks
Teva finalizes settlement with FTC to resolve all outstanding litigation »

Teva Pharmaceutical…

TEVA

Teva

$18.01

0.02 (0.11%)

AGN

Allergan

$137.94

-1.13 (-0.81%)

ABBV

AbbVie

$80.50

-0.35 (-0.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 22

    Feb

  • 25

    Feb

  • 18

    May

  • 28

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.